Mankind Pharma Limited (NSE:MANKIND)
India · Delayed Price · Currency is INR 2,166.80
+17.90 (0.83%)
At close: Dec 11, 2025
Mankind Pharma Revenue
Mankind Pharma had revenue of 36.97B INR in the quarter ending September 30, 2025, with 20.17% growth. This brings the company's revenue in the last twelve months to 135.46B, up 22.94% year-over-year. In the fiscal year ending March 31, 2025, Mankind Pharma had annual revenue of 122.07B with 18.98% growth.
Revenue (ttm)
135.46B
Revenue Growth
+22.94%
P/S Ratio
6.60
Revenue / Employee
5.02M
Employees
26,978
Market Cap
894.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 122.07B | 19.47B | 18.98% |
| Mar 31, 2024 | 102.60B | 15.11B | 17.27% |
| Mar 31, 2023 | 87.49B | 9.68B | 12.44% |
| Mar 31, 2022 | 77.82B | 15.67B | 25.22% |
| Mar 31, 2021 | 62.14B | 3.43B | 5.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |